Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 5/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | AKT2 | P31751 | 2/20 | 0.31 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.30 |
| ▸ | FABP3 | P05413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22778250 | 0.89 | LPAR1 (0.43) | LPAR1LPAR3PLA2G2CCA1CA2 | |
| SCHEMBL22778183 | 0.87 | LPAR1 (0.45) | LPAR1LPAR3PLA2G2CLPAR2AKT1 | |
| SCHEMBL22778213 | 0.87 | PLA2G2A (0.38) | LPAR1LPAR3CA1CA2CA7 | |
| SCHEMBL9237355 | 0.84 | PLA2G2C (0.37) | LPAR1LPAR3PLA2G2CCA1CA2 | |
| Alcohol SCHEMBL28910422 | 0.84 | LPAR3 (0.49) | LPAR1LPAR3CA1CA2CA7 | |
| Methyl Alcohol SCHEMBL28536635 | 0.83 | LPAR3 (0.48) | LPAR1LPAR3CA1CA2CA7 | |
| SCHEMBL28528617 | 0.83 | CA1 (0.38) | LPAR1LPAR3CA1CA2CA7 | |
| SCHEMBL461952 | 0.83 | PLA2G2C (0.45) | LPAR1LPAR3PLA2G2CCA1CA2 | |
| SCHEMBL28002680 | 0.83 | LPAR3 (0.46) | LPAR1LPAR3CA1CA2CA7 | |
| SCHEMBL28206699 | 0.83 | LPAR3 (0.46) | LPAR1LPAR3CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3982932-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | Dnalite Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| CN-114286671-A | Compositions and methods for biological delivery vehicles | DNALite治疗学公司 | 2022-04-05 | — | — | CN | claimed |
| WO-2020252375-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | claimed |
| US-20240058454-A1 | BIOLOGICAL DELIVERY SYSTEMS | PARTICELLA INC (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4259099-A1 | BIOLOGICAL DELIVERY SYSTEMS | Particella, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230023615-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | PARTICELLA, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220296516-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | PARTICELLA, INC. | 2022-09-22 | — | — | US | disclosed |
| WO-2022132678-A1 | BIOLOGICAL DELIVERY SYSTEMS | DNALITE THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-3982932-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | Dnalite Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114286671-A | Compositions and methods for biological delivery vehicles | DNALite治疗学公司 | 2022-04-05 | — | — | CN | disclosed |
| US-20210177982-A1 | MUCUS-PENETRATING PEPTIDES, DELIVERY VEHICLES AND METHODS OF THERAPY | DNALITE THERAPEUTICS, INC. | 2021-06-17 | — | — | US | disclosed |
| WO-2021119585-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-3796892-A2 | MUCUS-PENETRATING PEPTIDES, DELIVERY VEHICLES AND METHODS OF THERAPY | Dnalite Therapeutics, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| CN-112367974-A | Mucus penetrating peptides, delivery vehicles, and methods of treatment | DNALite治疗学公司 | 2021-02-12 | — | — | CN | disclosed |
| WO-2020252375-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177982-A1 | MUCUS-PENETRATING PEPTIDES, DELIVERY VEHICLES AND METHODS OF THERAPY | MUC1, VIP, CFTR | LPAR1 1659/4885LPAR3 1431/4885PLA2G2C 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.